Zai Lab/$ZLAB
Zai Lab shares rise after its Q3 loss came in narrower than analysts expected and the company highlighted promising zoci trial results in small-cell lung cancer.
7 hours agoLightyear AI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Zai Lab
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
- Ticker
- $ZLAB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,784
- Headquarters
- Pudong, China
- Website
- www.zailaboratory.com
Zai Lab Metrics
BasicAdvanced
$2.8B
-
-$1.78
-
-
Price and volume
Market cap
$2.8B
52-week high
$27.50
52-week low
$15.96
Average daily volume
998K
Financial strength
Current ratio
2.037
Quick ratio
1.497
Long term debt to equity
0.017
Total debt to equity
0.475
Interest coverage (TTM)
-45.16%
Profitability
EBITDA (TTM)
-261.814
Gross margin (TTM)
4.68%
Net profit margin (TTM)
-44.91%
Operating margin (TTM)
-62.99%
Effective tax rate (TTM)
2.16%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
-15.93%
Return on equity (TTM)
-29.99%
Valuation
Price to revenue (TTM)
5.701
Price to book
4.51
Price to tangible book (TTM)
5.35
Price to free cash flow (TTM)
-12.772
Free cash flow yield (TTM)
-7.83%
Free cash flow per share (TTM)
-1.769
Growth
Revenue change (TTM)
0.02%
Earnings per share change (TTM)
-7.41%
3-year revenue growth (CAGR)
18.79%
3-year earnings per share growth (CAGR)
-17.08%
What the Analysts think about Zai Lab
Analyst ratings (Buy, Hold, Sell) for Zai Lab stock.
Analyst projections of the future price of Zai Lab stock.
Bulls say / Bears say
Zoci’s early first-line small-cell lung cancer results look strong: with atezolizumab it achieved an 81.8% confirmed response rate and an estimated 81.9% six-month progression-free survival in 33 patients, with grade 3 or higher zoci-related events in 9.1%. A global Phase 3 trial is planned, giving Zai a potentially important catalyst if the results hold up. (Zai Lab Limited)
In previously treated extrapulmonary neuroendocrine cancers, zoci produced a 40% response rate among 60 patients. After FDA feedback, Zai plans to pursue potential accelerated approval, with fuller data expected in 2027. (Zai Lab Limited)
The commercial business showed signs of stabilising: Q3 net product revenue rose 2% from Q2, led by NUZYRA and early KarXT sales, and the China business remained profitable. Zai expects year-on-year product revenue growth to return in 2027. (Zai Lab Limited)
Sales are still falling year on year: Q3 revenue declined 6.8%, while ZEJULA and OPTUNE revenue fell 23.9% and 38.2%, respectively. Generic pricing pressure and competition are weighing on key products. (Zai Lab Limited, Yahoo Finance)
Zai remains loss-making: it reported a $46.1 million Q3 net loss, while cash, restricted cash and short-term investments fell to $659.7 million from $717.5 million at the end of Q2. Continued pipeline investment could keep pressure on its finances. (Zai Lab Limited)
Zoci remains an early-stage, high-risk bet: its striking first-line results come from just 33 patients, and the planned global Phase 3 trial has yet to provide confirmatory results. A weaker or delayed readout could undermine a key source of future growth. (Zai Lab Limited, Zai Lab Limited)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
Zai Lab Financial Performance
Revenues and expenses
Zai Lab Earnings Performance
Company profitability
Upcoming events
No upcoming events
Zai Lab News
AllArticlesVideos
Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates
Business Wire2 days ago
Zai Lab's Zoci Shows 82% Response Rate in Early Lung Cancer Study
MarketBeat2 weeks ago
Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
Business Wire2 weeks ago
Funds containing Zai Lab
Fund name | Fund size | $ZLAB weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.06% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.